Medtronic rises after FDA approves new heart lead

Shares of medical device maker Medtronic MDT.N rise 2% to $87.79 premarket

Co says its defibrillation lead, OmniaSecure, approved by the U.S. FDA

A defibrillation lead is a wire that delivers shocks to the heart to correct arrhythmias or irregular heart rhythms

The wire connects the heart to a device, known as a defibrillator, implanted in the body that applies an electric charge or shock to prevent sudden cardiac arrest

Co says device is the first to be cleared for placement in the heart's left bundle branch area, helping it beat in a natural way

Adds FDA's approval backed by global study showing 100% success in stopping abnormal rhythms with low complications

OmniaSecure can be used in adults and children aged 12 and older and may help heart failure patients needing resynchronization therapy - MDT

Shares down ~10% YTD vs. ~20% rise in 2025